Previous Close | 1.4900 |
Open | 1.4500 |
Bid | 1.4600 x 1100 |
Ask | 1.5700 x 3000 |
Day's Range | 1.5300 - 1.5300 |
52 Week Range | 1.0400 - 7.8600 |
Volume | |
Avg. Volume | 37,240 |
Market Cap | 17.647M |
Beta (5Y Monthly) | 0.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7660 |
Earnings Date | Nov 16, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for NNVC
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission.
NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate NV-CoV-2 to combat COVID-19. NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, althoug
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis.